2 results
Approved WMOWill not start
To compare the progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing) with those treated with placebo.
Not approvedWill not start
PRIMARY OBJECTIVE To characterize the pharmacokinetics (PK) of single doses of solriamfetolin pediatric subjects with narcolepsy.SECONDARY OBJECTIVE To assess the safety and tolerability of single doses of solriamfetol inpediatric subjects with…